Actual status of antiinterleukin-1 therapies in rheumatic diseases
M Geyer, U Müller-Ladner - Current opinion in rheumatology, 2010 - journals.lww.com
M Geyer, U Müller-Ladner
Current opinion in rheumatology, 2010•journals.lww.comOwing to the observation that IL-1 is not only involved in signaling processes resulting in
autoimmune and crystal-induced joint destruction but also in several hereditary
autoinflammatory syndromes, its value both in pathophysiology as well as for novel
advances in medication has significantly improved in the past years leading to an
enrichment of the current therapeutic armamentarium for the affected patients.
autoimmune and crystal-induced joint destruction but also in several hereditary
autoinflammatory syndromes, its value both in pathophysiology as well as for novel
advances in medication has significantly improved in the past years leading to an
enrichment of the current therapeutic armamentarium for the affected patients.
Summary
Owing to the observation that IL-1 is not only involved in signaling processes resulting in autoimmune and crystal-induced joint destruction but also in several hereditary autoinflammatory syndromes, its value both in pathophysiology as well as for novel advances in medication has significantly improved in the past years leading to an enrichment of the current therapeutic armamentarium for the affected patients.
Lippincott Williams & Wilkins